{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:53:46Z","timestamp":1791921226106,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","award":["SG-23-1061717"],"award-info":[{"award-number":["SG-23-1061717"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2022-00775"],"award-info":[{"award-number":["2022-00775"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ERA PerMed","award":["ERAPERMED2021-184"],"award-info":[{"award-number":["ERAPERMED2021-184"]}]},{"name":"The Knut and Alice Wallenberg foundation","award":["2017-0383"],"award-info":[{"award-number":["2017-0383"]}]},{"name":"The Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson\u2019s disease) at Lund University"},{"name":"The Swedish Alzheimer Foundation","award":["AF-980907"],"award-info":[{"award-number":["AF-980907"]}]},{"name":"The Swedish Brain Foundation","award":["FO2021-0293"],"award-info":[{"award-number":["FO2021-0293"]}]},{"name":"The Parkinson foundation of Sweden","award":["1412\/22"],"award-info":[{"award-number":["1412\/22"]}]},{"name":"The Cure Alzheimer\u2019s fund"},{"name":"The Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse"},{"name":"The Sk\u00e5ne University Hospital Foundation","award":["2020-O000028"],"award-info":[{"award-number":["2020-O000028"]}]},{"name":"Regionalt Forskningsst\u00f6d","award":["2022-1259"],"award-info":[{"award-number":["2022-1259"]}]},{"name":"The Swedish federal government under the ALF agreement","award":["2022-Projekt0080"],"award-info":[{"award-number":["2022-Projekt0080"]}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Pre-analytical factors can cause substantial variability in the measurements of cerebrospinal fluid (CSF) and plasma biomarkers of Alzheimer\u2019s disease (AD). However, their effects on the performance of one of the most promising plasma AD biomarkers, phosphorylated tau (p-tau)217, are not known.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included 50 amyloid-\u03b2 positive (A\u03b2<jats:sup>+<\/jats:sup>) and 50 A\u03b2<jats:sup>\u2212<\/jats:sup> participants from the Swedish BioFINDER-1 study. Plasma and CSF p-tau217 were measured using an immunoassay developed by Lilly Research Laboratories. We examined the effect of four plasma handling conditions, i.e., (1) thawing at room temperature (RT) with no\u00a0centrifugation, (2) thawing at RT followed by\u00a0centrifugation, (3) thawing on ice with no\u00a0centrifugation, and (4) thawing on ice followed by centrifugation. In addition, we also tested the effects of up to 3 freeze\u2013thaw cycles on the associations of plasma p-tau217 with AD-related pathologies measured with CSF p-tau217 and CSF A\u03b242\/A\u03b240.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the whole cohort (combining A\u03b2<jats:sup>+<\/jats:sup> and A\u03b2<jats:sup>\u2212<\/jats:sup> participants), we found significant correlations between plasma p-tau217 and both CSF p-tau217 (<jats:italic>R<\/jats:italic><jats:sub>range,<\/jats:sub> 0.614\u20130.717, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and CSF A\u03b242\/A\u03b240 (Spearman <jats:italic>R<\/jats:italic><jats:sub>range<\/jats:sub>,\u2009\u2212\u20090.515 to\u2009\u2212\u20090.652, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) for each of the four tested conditions. Correlations between plasma and CSF p-tau217 were also significant for all conditions in the A\u03b2<jats:sup>+<\/jats:sup> group (<jats:italic>R<\/jats:italic><jats:sub>range<\/jats:sub>, 0.506\u20130.579, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). However, in this A\u03b2<jats:sup>+<\/jats:sup> subgroup, correlations with CSF A\u03b242\/A\u03b240 were only significant for centrifuged samples (thawed at RT, <jats:italic>R<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.394, <jats:italic>p<\/jats:italic>\u2009=\u20090.010; thawed on ice, <jats:italic>R<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.406; <jats:italic>p<\/jats:italic>\u2009=\u20090.007). In A\u03b2<jats:sup>\u2212<\/jats:sup> participants, correlations between plasma and CSF p-tau217 were again significant only for centrifuged samples (thawed at RT, <jats:italic>R<\/jats:italic>\u2009=\u20090.394, <jats:italic>p<\/jats:italic>\u2009=\u20090.007; thawed on ice, <jats:italic>R<\/jats:italic>\u2009=\u20090.334; <jats:italic>p<\/jats:italic>\u2009=\u20090.022), with no correlations seen between plasma p-tau217 and CSF A\u03b242\/A\u03b240 for any of the conditions. While the accuracy of plasma p-tau217 to identify individuals with abnormal CSF A\u03b242\/A\u03b240 or CSF p-tau217 status was high, the AUCs for samples thawed at RT and analyzed without centrifugation were numerically lower than the AUCs of other conditions (CSF A\u03b242\/A\u03b240\u2009=\u20090.845 vs 0.872\u20130.884; CSF p-tau217\u2009=\u20090.866 vs 0.908\u20130.924, <jats:italic>p<\/jats:italic><jats:sub>diff<\/jats:sub>\u2009&gt;\u20090.11). P-tau217 concentration was consistently higher in non-centrifuged samples than in centrifuged samples (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.021). There were no differences between samples freeze-thawed once, twice, or three times.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Centrifugation improved the performance of plasma p-tau217, but thawing temperatures and up to three freeze\u2013thaw cycles did not have a significant impact. These results may inform the future development of standardized sample-handling protocols for AD biomarkers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-024-01391-1","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:02:29Z","timestamp":1707368549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effects of certain pre-analytical factors on the performance of plasma phospho-tau217"],"prefix":"10.1186","volume":"16","author":[{"given":"Divya","family":"Bali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"1391_CR1","unstructured":"Dementia [Internet]. Vol. 2. 2022 [cited 2023 Feb 15]. p. 2003\u20135. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"1391_CR2","unstructured":"Alzheimer\u00b4s Association [Internet]. 2023 [cited 2023 May 9]. Alzheimer\u2019s disease facts and figures. Available from: https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures."},{"key":"1391_CR3","doi-asserted-by":"publisher","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med [Internet]. 2021;27(6):954\u201363. Available from: https:\/\/doi.org\/10.1038\/s41591-021-01382-x.","DOI":"10.1038\/s41591-021-01382-x"},{"issue":"2","key":"1391_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/WCO.0000000000000904","volume":"34","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Cullen NC, Mattsson-Carlgren N, Hansson O. Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer\u2019s disease. Curr Opin Neurol. 2021;34(2):266\u201374.","journal-title":"Curr Opin Neurol"},{"key":"1391_CR5","doi-asserted-by":"publisher","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging [Internet]. 2023;3(5):506\u201319. Available from: https:\/\/doi.org\/10.1038\/s43587-023-00403-3.","DOI":"10.1038\/s43587-023-00403-3"},{"issue":"11","key":"1391_CR6","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain. 2020;143(11):3234\u201341.","journal-title":"Brain"},{"issue":"2","key":"1391_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78(2):149\u201356.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1391_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"issue":"9","key":"1391_CR9","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 2021;78(9):1108\u201317.","journal-title":"JAMA Neurol"},{"issue":"9","key":"1391_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739\u201352.","journal-title":"Lancet Neurol"},{"key":"1391_CR11","doi-asserted-by":"crossref","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. 2020;217(11):e20200861.","DOI":"10.1084\/jem.20200861"},{"key":"1391_CR12","doi-asserted-by":"publisher","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med [Internet]. 2022;28(12):2555\u201362. Available from: https:\/\/doi.org\/10.1038\/s41591-022-02074-w.","DOI":"10.1038\/s41591-022-02074-w"},{"issue":"10","key":"1391_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jalz.2018.05.008","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer\u2019s disease diagnosis: a review. Alzheimers Dement. 2018;14(10):1313\u201333.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1391_CR14","volume":"12","author":"O Hansson","year":"2020","unstructured":"Hansson O, Rutz S, Zetterberg H, Bauer E, H\u00e4hl T, Manuilova E, et al. Pre-analytical protocol for measuring Alzheimer\u2019s disease biomarkers in fresh CSF. Alzheimers Dement (Amst). 2020;12(1): e12137.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"3","key":"1391_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1391_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12168","volume":"13","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Su\u00e1rez-Calvet M, Karikari TK, Lantero-Rodriguez J, Snellman A, Sauer M, et al. Effects of pre-analytical procedures on blood biomarkers for Alzheimer\u2019s pathophysiology, glial activation, and neurodegeneration. Alzheimers Dement (Amst). 2021;13(1): e12168.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"8","key":"1391_CR17","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, et al. Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. 2022;18(8):1484\u201397.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1391_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/jnc.15757","volume":"165","author":"C Kurz","year":"2023","unstructured":"Kurz C, St\u00f6ckl L, Schrurs I, Suridjan I, G\u00fcrsel S\u00dc, Bittner T, et al. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer\u2019s disease. J Neurochem. 2023;165(1):95\u2013105.","journal-title":"J Neurochem"},{"issue":"2","key":"1391_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12439","volume":"15","author":"AL Sunde","year":"2023","unstructured":"Sunde AL, Alsnes IV, Aarsland D, Ashton NJ, Tovar-Rios DA, De Santis G, et al. Preanalytical stability of plasma biomarkers for Alzheimer\u2019s disease pathology. Alzheimers Dement (Amst). 2023;15(2): e12439.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1391_CR20","doi-asserted-by":"crossref","unstructured":"Mansilla A, Canyelles M, Ferrer R, Arranz J, Rodr\u00edguez-Baz \u00cd, Zhu N, et al. Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer\u2019s disease. Clin Chem Lab Med [Internet]. 2023; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37083158.","DOI":"10.1515\/cclm-2023-0245"},{"issue":"4","key":"1391_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(4):1204\u201315.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1391_CR22","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146(4):1592\u2013601.","journal-title":"Brain"},{"issue":"2","key":"1391_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimers Dement. 2022;18(2):283\u201393.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1391_CR24","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403\u201314.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1391_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"O Hansson","year":"2010","unstructured":"Hansson O, Batrla Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1391_CR26","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun. 2020;11(1):1683.","journal-title":"Nat Commun"},{"issue":"12","key":"1391_CR27","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement"},{"key":"1391_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-1-61779-068-3_17","volume":"728","author":"RL Sparrow","year":"2011","unstructured":"Sparrow RL, Greening DW, Simpson RJ. A protocol for the preparation of cryoprecipitate and cryodepleted plasma. Methods Mol Biol. 2011;728:259\u201365.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"1391_CR29","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1373\/clinchem.2014.236679","volume":"61","author":"N Le Bastard","year":"2015","unstructured":"Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem. 2015;61(5):734\u201343.","journal-title":"Clin Chem"},{"key":"1391_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fneur.2015.00153","volume":"6","author":"MJ Leit\u00e3o","year":"2015","unstructured":"Leit\u00e3o MJ, Baldeiras I, Herukka SK, Pikkarainen M, Leinonen V, Simonsen AH, et al. Chasing the effects of pre-analytical confounders - A multicenter study on CSF-AD biomarkers. Front Neurol. 2015;6:153.","journal-title":"Front Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01391-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01391-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01391-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T09:02:35Z","timestamp":1707642155000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01391-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01391-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was executed in agreement with the Ethics Committee at Lund University, Sweden. All study participants have signed an informed consent form in order to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Figure\u00a0 is original and was created using BioRender.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2\u00a0years, he has received consultancy\/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi, and Siemens.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}